Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368472 · ClinicalTrials.gov registry record · Phase 2
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00368472 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 138 participants.
The verdict
NCT00368472, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
Interventions
- DRUG Perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368472
The ClinicalTrials.gov registry entry for NCT00368472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perampanel is the first listed.
NCT00368472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00368472 about?
NCT00368472 is a clinical study titled "4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures". The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
What is the current status of trial NCT00368472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2006-10. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00368472?
The interventions under investigation include: Perampanel (DRUG).
Who is sponsoring clinical trial NCT00368472?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.